Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02060370 · ClinicalTrials.gov registry record · Phase 2
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
A Phase 2 study of Kidney Cancer and Genitourinary Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT02060370: Completed Phase 2 study of Kidney Cancer and Genitourinary Cancer, sponsored by M.D. Anderson Cancer Center.
NCT02060370 is a Phase 2 study of Kidney Cancer and Genitourinary Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02060370, a Phase 2 study of Kidney Cancer and Genitourinary Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical research study is to learn more about the safety of giving sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which they receive no drug. Researchers want to learn more about the side effects of the drug and the effects of a different dosing schedule.
Primary Outcome
Determine the number of participants who experience a specific, treatment-related adverse events at a grade three, four or five: fatigue, hand-foot syndrome, and/or diarrhea. Adverse events as defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 4
Conditions Studied
Interventions
- DRUG Sunitinib
- BEHAVIORAL Questionnaire
Study Locations (5)
California
- Stanford University Medical Center - Stanford
North Carolina
- Lineberger Cancer Center - Chapel Hill
Ohio
- Cleveland Clinic Taussig Cancer Institute - Cleveland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-08 |
| Est. Completion | 2019-01-02 |
| Phase | Phase 2 |
What the finished NCT02060370 record still lists
NCT02060370 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.
NCT02060370 lists 5 locations in 5 states (California, North Carolina, Ohio).
Frequently Asked Questions
What is clinical trial NCT02060370 about?
NCT02060370 is a clinical study titled "Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)". The goal of this clinical research study is to learn more about the safety of giving sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which they receive no drug. Researchers want to learn more about the side effects of the drug and the effects of a different dosi...
What is the current status of trial NCT02060370?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2014-08. Estimated completion is 2019-01-02.
What conditions does trial NCT02060370 study?
This clinical trial studies the following conditions: Kidney Cancer, Genitourinary Cancer.
What interventions are being tested in trial NCT02060370?
The interventions under investigation include: Sunitinib (DRUG), Questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT02060370?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02060370 being conducted?
This trial has 5 study locations across California, North Carolina, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02060370's enrollment target sits among peer trials
60 30th of 60 higher than 29 of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia